Zheng Yu-ling's Experience of Treating Lung-Cancer Chest Pain with Ginseng Toxin-Resolving Powder

ZHU Ran-pei; ZHENG Yu-ling; ZHANG Ya-ling

doi:10.16367/j.issn.1003-5028.2021.11.0376

Suggestions

您当前的位置：

首页 >

文章列表页 >

Zheng Yu-ling's Experience of Treating Lung-Cancer Chest Pain with Ginseng Toxin-Resolving Powder

Previous: Tong Xiaolin's experience in using rhubarb root and rhizome, golden thread and areca seed to treat type 2 diabetes with the gastrointestinal excessive heat syndrome

Next: Yan Jun's Experience of Treating Unexplained Fever

Zheng Yu-ling's Experience of Treating Lung-Cancer Chest Pain with Ginseng Toxin-Resolving Powder
1.Henan University of Chinese Medicine, Zhengzhou, Henan, China, 450046
DOI：10.16367/j.issn.1003-5028.2021.11.0376

扫描看全文

ZHU Ran-pei, ZHENG Yu-ling, ZHANG Ya-ling. Zheng Yu-ling's Experience of Treating Lung-Cancer Chest Pain with Ginseng Toxin-Resolving Powder[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.16367/j.issn.1003-5028.2021.11.0376
DOI：

ZHU Ran-pei, ZHENG Yu-ling, ZHANG Ya-ling. Zheng Yu-ling's Experience of Treating Lung-Cancer Chest Pain with Ginseng Toxin-Resolving Powder[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.16367/j.issn.1003-5028.2021.11.0376 DOI：

摘要

郑玉玲教授认为，肺癌胸痛大多是在正气亏虚、肺气不足的基础上，邪气侵袭，潜于肺络，因虚不能驱散，久之伏藏致肺络受损而成，乃本虚标实之证，运用人参败毒散治疗肺癌胸痛，以益气通络为治疗大法，以气虚络阻为辨证要点，常获显效。此外，郑教授认为，恶性肿瘤为慢性消耗性疾病，久之必会消耗正气，脾胃为后天之本，气血生化之源，肿瘤患者应加强营养，临床用药多以顾护胃气为本，尤其重视患者的饮食调适，注重扶正祛邪，以固护患者正气为主。同时，郑教授认为中医药治疗肿瘤，首先应坚持中医思维、整体观念、辨证论治，同时亦应不断吸取西医学研究的新成果、新技术和新方法，主张中西医并重，优势互补。

Abstract

Professor Zheng Yu-ling believes that lung-cancer chest pain is mostly based on deficiency of healthy ,qi, and insufficient lung ,qi,. Pathogenic ,qi, invades and hides in the lung collaterals, which cannot be dissipated due to deficiency, and lung collaterals are then damaged. It is a syndrome of deficient root cause and excessive manifestations. Professor Zheng often uses Ginseng Toxin-Resolving Powder to treat it by supplementing ,qi, and dredging collaterals as the principle and regarding ,qi, deficiency dredging collaterals as the key points of syndrome differentiation, and has always achieved good efficacy. In addition, she believes that malignant tumors are chronic consumptive diseases, which will consume healthy ,qi, for a long time. The spleen and stomach provide the material basis of the acquired constitution and the source of ,qi,-blood formation, so in clinical practice, she always adopts proper drugs for protecting stomach ,qi, pays special attention to the dietary adjustment of patients, strengthening healthy ,qi, and removing pathogens, and mainly protects the healthy ,qi, of patients. At the same time, Professor Zheng believes that when treating tumors with TCM, we should adhere to TCM thinking, concept holism and syndrome differentiation and treatment. It is also necessary to constantly absorb the new achievements, new technologies and new methods of Western medicine research, and advocate integrated traditional Chinese and Western medicine and have complementary advantages.

关键词

肺癌胸痛恶性肿瘤人参败毒散郑玉玲

Keywords

lung-cancer chest painmalignant tumorGinseng Toxin-Resolving PowderZheng Yu-ling

references

胡颖.羟考酮控释片联合甲强龙治疗中重度肺癌癌痛的临床疗效[J].临床合理用药杂志, 2020, 13(27): 47-48.

张倩倩.中药贴敷法治疗癌性疼痛的研究现状[J].中医临床研究, 2017, 9(13): 144-146.

陈琼, 刘曙正, 郭兰伟, 等.2016年河南省恶性肿瘤的发病与死亡分析[J].中国肿瘤, 2020, 29(8): 571-578.

苏雷, 魏秀芹.从我国肺癌防控发展看早期肺癌的诊疗策略[J].医学研究杂志, 2020, 49(9): 1-5.

刘宗超, 李哲轩, 张阳, 等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.

葛均波, 徐永健.内科学[M].8版.北京: 人民卫生出版社, 2013: 78-79.

刘晨阳, 赵世林, 杨婕, 等.梅花针叩刺联合氨酚羟考酮治疗肺癌术后慢性疼痛的效果观察[J].癌症进展, 2021, 19(6): 570-574.

贺佐梅, 曾普华, 郜文辉, 等.7435份非小细胞肺癌病案中医证候分布频数及关联分析[J].中医药导报, 2019, 25(16): 40-44.

宋鑫, 黄佩茹, 凌婉雯, 等.癌性疼痛中医内治法研究探析[J].亚太传统医药, 2021, 17(5): 213-216.

王丁超, 周素贞.李建生论治肺癌经验[J].河南中医, 2020, 40(6): 855-858.

洪永贵.郑玉玲教授论治肺癌经验[J].中国中医急症, 2006, 15(9): 1002-1003.

太平惠民和剂局.太平惠民和剂局方[M].刘景源，点校.北京: 人民卫生出版社, 1985: 51.

钱乙.小儿药证直诀[M].北京: 中国医药科技出版社, 2016: 93.

谢鸣.方剂学[M].3版.北京: 人民卫生出版社, 2016: 76.

陶御风.皕-选方治验实录[J].北京：人民卫生出版社, 2011: 99-100.

陈宗光, 陈奇.人参败毒散新用[J].新中医, 1994, 26(2): 57.

乔洪华.人参败毒散临床运用举隅[J].四川中医, 1999, 17(3): 53-54.

董卫国.人参败毒散临床新用[N].中国中医药报, 2009-3-6(5).

李东东, 王姗姗, 杨素清.人参败毒散类方在皮肤科当代应用[J].辽宁中医药大学学报, 2018, 20(3): 69-72.

孙广仁.中医基础理论[M].2版.北京: 中国中医药出版社, 2007.

陈家旭.中医诊断学[M].北京: 中国中医药出版社, 2015: 169.

高洁, 张冬利, 杨红群.人参败毒散治疗气虚感冒疗效观察[J].山西中医, 2019, 35(9): 49.

刘源, 刘金豹, 彭伟.人参败毒散治疗新型冠状病毒肺炎(COVID-19)作用机制的网络药理学探讨[J].中药材, 2020, 43(6): 1531-1539.

乔雪涵, 岳丽玲, 朱文斌.人参皂苷Rg3的抗肿瘤作用研究现状[J].中国临床药理学杂志, 2021, 37(10): 1272-1276.

周璐丽, 曾建国.独活化学成分及药理活性研究进展[J].中国现代中药, 2019, 21(12): 1739-1748.

程海霞, 段清珍.柴胡皂苷D抗肿瘤作用机制研究进展[J].山西中医, 2021, 37(2): 57-60.

魏科, 陈勇超, 周家豪, 等.茯苓多糖辅助抗肺癌及免疫调节作用研究[J].中华中医药杂志, 2020, 35(10): 4937-4940.

邢娜, 舒尊鹏, 徐炳清, 等.不同产地枳壳挥发油成分的气相色谱-质谱分析及抗肿瘤活性研究[J].中医药信息, 2015, 32(5): 1-6.

沈漫, 吴宇娟, 李医明, 等.桔梗皂苷药理学及临床应用研究进展[J].上海中医药大学学报, 2018, 32(5): 86-91.

迟笑怡, 周天, 胡凯文.川芎对恶性肿瘤侵袭与转移影响研究进展[J].中医学报, 2019, 34(3): 495-500.

谭晖, 李恩孝, 李毅, 等.人参皂苷Rh1通过Wnt通路抑制肺腺癌A549细胞增殖的机制探讨[J].现代肿瘤医学, 2020, 28(18): 3134-3137.

王艳.人参皂苷Rg3对人肺腺癌细胞株抗肿瘤作用及相关机制的研究[D].哈尔滨: 黑龙江中医药大学, 2011.

王布, 张志华, 顾鑫, 等.川芎嗪注射液联合顺铂注射剂对lewis肺腺癌小鼠移植瘤生长及血管生成的抑制作用[J].中国临床药理学杂志, 2016, 32(22): 2085-2088.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Discussing Syndrome Differentiation and Treatment of Middle and Late Tumors Based on the Theory of Consumptive Disease in Synopsis of the Golden Chamber

ProfessorWANG Xiaomin Discusses theAdverse effects of Molecular Targeted Therapy forMalignant Tumors from the Theory of Zhongyang Excretion

Related Author

No data

Related Institution

Hubei University of Chinese Medicine

Xinhua Hospital of Hubei University of Chinese Medicine, Hubei Provincial Hospital of Integrated Chinese and Western Medicine

Beijing Hospital of Traditional Chinese Medicine Affi liated to Capital Medical University

⁰